{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:47:38Z","timestamp":1768477658062,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13109-w","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:21:17Z","timestamp":1754025677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Presence of high-risk nano particulate matters in powder injection: microscopic evaluation and investigation of particles contamination"],"prefix":"10.1038","volume":"15","author":[{"given":"Yasir","family":"Mehmood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacky","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed H.","family":"AL Mughram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musaab","family":"Dauelbait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Bourhia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"6","key":"13109_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1179\/1973947814Y.0000000208","volume":"27","author":"I Arnet","year":"2015","unstructured":"Arnet, I. et al. Pharmaceutical quality of eight generics of ceftriaxone Preparation for injection in Eastern Asia. J. Chemother. 27(6), 337\u2013342 (2015).","journal-title":"J. Chemother."},{"key":"13109_CR2","doi-asserted-by":"crossref","unstructured":"Page, M. G. Beta-lactam antibiotics. In Antibiotic Discovery and Development 79\u2013117 (Springer, 2011).","DOI":"10.1007\/978-1-4614-1400-1_3"},{"issue":"4","key":"13109_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/antibiotics11040458","volume":"11","author":"G Loeuille","year":"2022","unstructured":"Loeuille, G. et al. Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy. Antibiotics 11(4), 458 (2022).","journal-title":"Antibiotics"},{"key":"13109_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2165\/00003495-198427060-00001","volume":"27","author":"D Richards","year":"1984","unstructured":"Richards, D. et al. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27, 469\u2013527 (1984).","journal-title":"Drugs"},{"issue":"1","key":"13109_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/10408347.2019.1676194","volume":"51","author":"XY Duan","year":"2021","unstructured":"Duan, X. Y. et al. Progress in pretreatment and analysis of cephalosporins: an update since 2005. Crit. Rev. Anal. Chem. 51(1), 55\u201386 (2021).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"13109_CR6","first-page":"21","volume":"30","author":"HM Owens","year":"2003","unstructured":"Owens, H. M. & Dash, A. K. Ceftriaxone sodium: comprehensive profile. Profiles of drug substances. Excipients Relat. Methodol. 30, 21\u201357 (2003).","journal-title":"Excipients Relat. Methodol."},{"issue":"1","key":"13109_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1086\/313620","volume":"30","author":"BJ Guglielmo","year":"2000","unstructured":"Guglielmo, B. J. et al. Ceftriaxone therapy for Staphylococcal osteomyelitis: a review. Clin. Infect. Dis. 30(1), 205\u2013207 (2000).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"13109_CR8","first-page":"1","volume":"3","author":"SA Tawde","year":"2014","unstructured":"Tawde, S. A. Particulate matter in injectables: main cause for recalls. J. Pharmacovigil. 3(1), 1\u20132 (2014).","journal-title":"J. Pharmacovigil."},{"key":"13109_CR9","unstructured":"Rasheed, H. Development of Simple and cost-effective High Performance Liquid Chromatography Methods for Quality Control of Essential beta-lactam Antibiotics in low-and middle-income Countries (Universit\u00e4t W\u00fcrzburg, 2019)."},{"issue":"2","key":"13109_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10408347.2021.1964342","volume":"53","author":"JR Matos","year":"2023","unstructured":"Matos, J. R. et al. Analytical methods for the quality control of veterinary antimicrobials medicines. Crit. Rev. Anal. Chem. 53(2), 384\u2013395 (2023).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"13109_CR11","unstructured":"USP, G. C. 788\u2009>\u2009Particulate Matter in Injections (The United States Pharmacopoeia\u2014National Formulary, 2016)."},{"issue":"3","key":"13109_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/microorganisms7030077","volume":"7","author":"M Henry","year":"2019","unstructured":"Henry, M. & Fouladkhah, A. Outbreak history, biofilm formation, and preventive measures for control of cronobacter Sakazakii in infant formula and infant care settings. Microorganisms 7(3), 77 (2019).","journal-title":"Microorganisms"},{"key":"13109_CR13","unstructured":"Narhi, L. O. et al. Filling the pharmacopeial gaps of visual inspection: toward standardization and consistency of visible particle testing. In Pharmacopeial Forum. (2021)."},{"key":"13109_CR14","unstructured":"Bliese, S. L. Developing Screening Technologies for Low Resource Settings (University of Notre Dame, 2021)."},{"issue":"16","key":"13109_CR15","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1039\/C4AN00380B","volume":"139","author":"HJ Jung","year":"2014","unstructured":"Jung, H. J. et al. Combined use of quantitative ED-EPMA, Raman microspectrometry, and ATR-FTIR imaging techniques for the analysis of individual particles. Analyst 139(16), 3949\u20133960 (2014).","journal-title":"Analyst"},{"issue":"6","key":"13109_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.5731\/pdajpst.2018.009027","volume":"72","author":"J Johns","year":"2018","unstructured":"Johns, J. et al. Achieving zero defects for visible particles in injectables. PDA J. Pharm. Sci. Technol. 72(6), 640\u2013650 (2018).","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"13109_CR17","first-page":"6947","volume":"42\u2013NF 37","author":"UP Convention","year":"2019","unstructured":"Convention, U. P. General chapter\u2009<\u2009790\u2009>\u2009visible particulates in injections. USP 42\u2013NF 37, 6947 (2019).","journal-title":"USP"},{"key":"13109_CR18","unstructured":"Shearer, G. L. Contaminant identification in pharmaceutical products. Microscope. 51(1), 3\u201310 (2003)."},{"key":"13109_CR19","unstructured":"Zona, C. McCrone Microscopes & Accessories: The Microscopist\u2019s Partner\u2014A Historical Perspective."},{"issue":"2","key":"13109_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1017\/S1551929500057436","volume":"8","author":"A Teetsov","year":"2000","unstructured":"Teetsov, A. Preparation and use of needles and micropipets for handling very small particles. Microsc. Today. 8(2), 8\u201316 (2000).","journal-title":"Microsc. Today"},{"key":"13109_CR21","doi-asserted-by":"crossref","unstructured":"Schwartz, W. WC Mccrone and JG Delly, The Particle Atlas, Vol. I. Principles and Technics, 347 Abbildungen, 49 Tabellen, 1 Farbtafel; Vol. II. The Light Microscopy Atlas, 609 farbige Abbildungen; Vol. III. The Electron Microscopy Atlas, 609 Abbildungen; Vol. IV. The Particle Analyst\u2019s Handbook, mit zahlreichen Abbildungen, Tabellen und Diagrammen. 1138 S. Ann. Arbor Michigan and Chichester (England). Ann. Arbor Sc. Publ. und J. Wiley and Sons 1973. Vol. I\u00a3 27.50, Vol. II\u2014IV je\u00a3 22.00, Wiley Online Library. (1975).","DOI":"10.1002\/jobm.3630150621"},{"issue":"2","key":"13109_CR22","first-page":"91","volume":"1","author":"M Perez","year":"2016","unstructured":"Perez, M. et al. Particulate matter in injectable drugs: evaluation of risks to patients. Pharm. Technol. Hosp. Pharm. 1(2), 91\u2013103 (2016).","journal-title":"Pharm. Technol. Hosp. Pharm."},{"issue":"1","key":"13109_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1365-2044.2003.296812.x","volume":"58","author":"S Lye","year":"2003","unstructured":"Lye, S. & Hwang, N. Glass particle contamination: is it here to stay? Anaesthesia 58(1), 93\u201394 (2003).","journal-title":"Anaesthesia"},{"issue":"3","key":"13109_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2648.2004.03195.x","volume":"48","author":"ST Preston","year":"2004","unstructured":"Preston, S. T. & Hegadoren, K. Glass contamination in parenterally administered medication. J. Adv. Nurs. 48(3), 266\u2013270 (2004).","journal-title":"J. Adv. Nurs."},{"key":"13109_CR25","doi-asserted-by":"crossref","unstructured":"Hecq, J. D. Centralized intravenous additive services (CIVAS): the state of the art in 2010. In Annales Pharmaceutiques Fran\u00e7aises (Elsevier, 2011).","DOI":"10.1016\/j.pharma.2010.09.002"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13109-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:11:43Z","timestamp":1757326303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13109-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13109"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13109-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28059"}}